$49 per month*
Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights Emergent BioSolutions Revenue by Segment, split between Contract Development and Manufacturing Services, Contracts and Grants, and Product and Net Sales, reported on quarterly basis from Q1 2016 onwards.
|Revenue by Segment||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
|Product and net sales||$202.20||$181.20||$270.50||82.21%|
|Contract development and manufacturing services||$157.10||$190.90||$41.60||14.67%|
|Contracts and grants||$25.90||$25.40||$16.90||5.13%|
(All the figures in millions, except the percentages)
Emergent Biosolutions specializes in therapies that treat and protect against public health threats. It offers vaccines and medicines.
In the year 2020, Emergent BioSolution generated total revenue of $972.40 million, which increased in the next year 2021 to $1,069.50 million, showing year-on-year growth of 9.07%. In Q3 2020, it reported total revenue of $385.20 million, which decreased in Q3 2021 to $329.00, showing a quarter-on-quarter decline of 14.54%. In Q2 2021, the company earned total revenue of $397.50, which further declined by 22.27% in Q3 2021.
Revenue of Emergent BioSolution is further bifurcated in the following segments:
Emergent BioSolutions develops, manufactures, and supplies medical countermeasures. It provides a wide range of medical products including ANTHRASIL (Anthrax, Immune Globulin Intravenous), BAT (Botulism Antitoxin Heptavalent), BioThrax (Anthrax Vaccine Adsorbed), NARCAN (naloxone, HCI), RSDL (Reactive Skin Lotion Kit), and many more. It is one of the major earning sources of the company among all segments.
In the year 2020, the product and net sales segment reported total revenue of $648.90 million, which further shows a decline of $589.60 in the year 2021, depicting a year-on-year fall of 9.13%. In Q3 2020, it generated revenue of $202.20 million, which further increased in Q3 2021, showing quarter-on-quarter growth of 33.53%. It showed a slight decrease in Q2 2021; it made revenue of $181.20, which increased to $270.50, in Q3 2021, and contributed 82.21% to the total revenue of the company.
The company works as a contractor and outsourced products among trusted manufacturers, which helps the company to make a reliable profit, while ensuring the safety of the products and programs. The company also generates money through its services, charging monthly insurance premiums from thousands of customers. It earns the majority of revenue when the market value of another company’s products increases.
In the year 2020, contract development and manufacturing services earned total revenue of $251.40 million, which further increased to $416.30, in the year 2021, showing year-on-year growth of 39.61%. In Q3 2020, it reported revenue of $157.10 million; it has further shown a drastic decline to $41.60 million in Q3 2021 by 69.70%. In Q2 2021, this segment earned revenue of $190.90, which decreased in the next quarter, Q3 2021, and contributed only 14.67% to the company’s total revenue.
Emergent BioSolutions generates adequate revenue through the contract and grants segment; the company receives grants from various political parties, government-sponsored firms, and some private institutions. There are many NGOs that donate to Emergent BioSolutions.
In the year 2020, the contracts and grants segment generated revenue of $72.10 million, which showed a slight decrease and earned $63.60 million, in the year 2021, showing a year-on-year decline of 11.78%. In Q3 2020, it reported revenue of $25.90 million; it has further shown a drastic decline to $16.90 million in Q3 2021 by 34.74%. In Q2 2021, this segment earned revenue of $25.40, which decreased in the next quarter. Q3 2021; it merely contributed 5.13% to the total revenue of Emergent BioSolutions.
The company Emergent BioSolutions Incorporation is a public and American multinational company, operating globally. It was founded on 5 September 1998 and incorporated in 2003. It started as a private company, but later, in 2014, due to government share, it was declared as a public company. The company is headquartered in Gaithersburg, Maryland. The company trades as EBS, it develops and supplies vaccines and antibodies therapeutics for transmittable diseases and opioid overdoses. It also facilitates medical equipment for biodefense purposes.
The company creates pharmaceuticals for infectious diseases like typhoid and cholera. It offers medicines and vaccines for travel-related viruses and open sicknesses. Also, during the COVID-19 pandemic, the company manufactured two vaccines at a time; however, it faced many complications from the American government and it was disbanded. Emergent BioSolutions is transferring its services to more than 10 countries, including London, Singapore, and Dublin.
The company created an Auto-Injector platform, where infectious diseases can get rapid delivery of nerve antidotes and other emergency response, it provides on-the-spot treatment; it is used by self and especially it is made for soldiers so that they can treat selves. However, this isn’t certified or approved by the U.S. FDA. Emergent BioSolutions faces stiff competition from many companies including, Valneva, Ain AI Khaleej Hospital, Haemonetics, Tristel.
Did you like Emergent BioSolutions Revenue by Segment statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.